(Reuters) – Abbott has launched its over-the-counter continuous glucose monitoring system Lingo in the U.S., days after a rival started marketing its product.
Lingo is available for consumers 18 years and older not on insulin in three payment options – $49 for two weeks, $89 for four weeks and $249 for 12 weeks, the company said on Thursday.
Rival Dexcom (NASDAQ:DXCM) last month launched its over-the-counter system, Stelo, at a price of up to $99. Stelo is also priced at $89 for a four-week subscription.
Lingo tracks glucose in real-time and provides personalized insights to improve overall well-being.
Abbott received FDA clearance for Lingo, available in Britain since January for 120-150 pounds ($152-$190) per month, in June.
This post appeared first on investing.com
